JP2016513471A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513471A5
JP2016513471A5 JP2016502442A JP2016502442A JP2016513471A5 JP 2016513471 A5 JP2016513471 A5 JP 2016513471A5 JP 2016502442 A JP2016502442 A JP 2016502442A JP 2016502442 A JP2016502442 A JP 2016502442A JP 2016513471 A5 JP2016513471 A5 JP 2016513471A5
Authority
JP
Japan
Prior art keywords
codon
nucleic acid
seq
generates
recombinant nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513471A (ja
JP6506249B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/027447 external-priority patent/WO2014152534A1/en
Publication of JP2016513471A publication Critical patent/JP2016513471A/ja
Publication of JP2016513471A5 publication Critical patent/JP2016513471A5/ja
Priority to JP2019063498A priority Critical patent/JP6956965B2/ja
Application granted granted Critical
Publication of JP6506249B2 publication Critical patent/JP6506249B2/ja
Priority to JP2021153882A priority patent/JP7239948B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502442A 2013-03-14 2014-03-14 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法 Expired - Fee Related JP6506249B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019063498A JP6956965B2 (ja) 2013-03-14 2019-03-28 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
JP2021153882A JP7239948B2 (ja) 2013-03-14 2021-09-22 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361781228P 2013-03-14 2013-03-14
US61/781,228 2013-03-14
US201361890500P 2013-10-14 2013-10-14
US61/890,500 2013-10-14
PCT/US2014/027447 WO2014152534A1 (en) 2013-03-14 2014-03-14 Recombinant rsv with silent mutations, vaccines, and methods related thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019063498A Division JP6956965B2 (ja) 2013-03-14 2019-03-28 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法

Publications (3)

Publication Number Publication Date
JP2016513471A JP2016513471A (ja) 2016-05-16
JP2016513471A5 true JP2016513471A5 (https=) 2017-04-20
JP6506249B2 JP6506249B2 (ja) 2019-04-24

Family

ID=51581238

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016502442A Expired - Fee Related JP6506249B2 (ja) 2013-03-14 2014-03-14 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
JP2019063498A Active JP6956965B2 (ja) 2013-03-14 2019-03-28 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
JP2021153882A Active JP7239948B2 (ja) 2013-03-14 2021-09-22 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
JP2023025816A Pending JP2023062157A (ja) 2013-03-14 2023-02-22 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019063498A Active JP6956965B2 (ja) 2013-03-14 2019-03-28 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
JP2021153882A Active JP7239948B2 (ja) 2013-03-14 2021-09-22 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
JP2023025816A Pending JP2023062157A (ja) 2013-03-14 2023-02-22 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法

Country Status (8)

Country Link
US (4) US10232032B2 (https=)
EP (2) EP2970981B1 (https=)
JP (4) JP6506249B2 (https=)
CN (2) CN113322264B (https=)
AU (3) AU2014239583B2 (https=)
ES (1) ES2854673T3 (https=)
PL (1) PL2970981T3 (https=)
WO (1) WO2014152534A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113322264B (zh) 2013-03-14 2024-05-31 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
MX2018005462A (es) * 2015-10-29 2018-08-01 Univ Emory Composiciones inmunogénicas de rsv quimérico y métodos de uso.
PH12022552125A1 (en) 2016-04-05 2023-04-12 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
IL264119B2 (en) * 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
WO2019162532A1 (en) * 2018-02-26 2019-08-29 Stiftung Tierärztliche Hochschule Hannover (Tiho) Improved pneumovirus reverse genetics
JP2022513025A (ja) * 2018-11-13 2022-02-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された融合前ｒｓｖ ｆタンパク質
KR20210126075A (ko) * 2019-02-11 2021-10-19 에모리 유니버시티 키메라 rsv 및 hmpv f 단백질, 면역원성 조성물, 및 사용 방법
EP4319880A4 (en) * 2021-04-08 2025-03-19 Codagenix Inc. Method of eliciting an immune response against respiratory syncytial virus
US12304929B2 (en) * 2021-04-12 2025-05-20 Sk Bioscience Co., Ltd. Recombinant RSV live vaccine strain and the preparing method thereof
US20240082385A1 (en) * 2022-05-27 2024-03-14 Meissa Vaccines, Inc. Rsv vaccines and methods of administering same

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
AT401526B (de) 1993-02-10 1996-09-25 Scheirer Winfried Reagenzlösung zur stabilisierung der lumineszenz bei der luciferasemessung
PT702085E (pt) 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
AU727923B2 (en) 1995-09-27 2001-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of infectious respiratory syncytial virus from cloned nucleotide sequences
US6923971B2 (en) 1995-09-27 2005-08-02 The United States Of America As Represented By The Department Of Health & Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6214805B1 (en) * 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
EP0912724B1 (en) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6074859A (en) 1997-07-08 2000-06-13 Kikkoman Corporation Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
US20020018780A1 (en) 2000-05-25 2002-02-14 Scott Koenig Epitope-based vaccine for respiratory syncytial virus F-protein
CA2520671C (en) 2003-03-28 2014-03-18 Medimmune Vaccines, Inc. Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
CN1922309B (zh) 2003-12-24 2011-07-13 由卫生福利和体育大臣代表的荷兰王国 具有反式互补的基因组缺陷的呼吸道合胞病毒
DK3312272T3 (da) 2004-10-08 2019-12-02 Us Gov Health & Human Services Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US8772256B2 (en) * 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
EP4368202A3 (en) 2007-03-30 2024-08-21 The Research Foundation for The State University of New York Attenuated viruses useful for vaccines
WO2010039224A2 (en) 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
CA2742086A1 (en) 2008-11-05 2010-05-14 Merck Sharp & Dohme Corp. Live, attenuated respiratory syncytial virus
JP5813513B2 (ja) * 2008-12-09 2015-11-17 ノババックス，インコーポレイテッド 修飾ｒｓｖｆタンパク質及びその使用方法
EP4218799A1 (en) 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
US20110097358A1 (en) * 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
US10227569B2 (en) 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
DK2707385T3 (da) 2011-05-13 2017-11-20 Glaxosmithkline Biologicals Sa RSV-F-præfusionsantigener
US9492525B2 (en) 2011-07-06 2016-11-15 Nanobio Corporation Human respiratory syncytial virus vaccine
US8816081B2 (en) 2012-08-06 2014-08-26 Basf Se Boron containing perylene monoimides, a process for their production, their use as building blocks for the production of perylene monoimide derivatives, monoimide derivatives and their use in dye-sensitized solar cells
US9957486B2 (en) * 2013-02-08 2018-05-01 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
FI2970398T3 (fi) 2013-03-13 2024-08-06 Us Health Rsv f -prefuusioproteiineja ja niiden käyttö
CN113322264B (zh) * 2013-03-14 2024-05-31 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
MX2018005462A (es) 2015-10-29 2018-08-01 Univ Emory Composiciones inmunogénicas de rsv quimérico y métodos de uso.

Similar Documents

Publication Publication Date Title
JP2016513471A5 (https=)
CN103442731B (zh) 表达系统
ES2839880T3 (es) Vacuna contra el VRS
CN106661091B (zh) 流行性感冒病毒疫苗及其用途
JP2014530010A5 (https=)
JP2010227101A5 (https=)
US20220411474A1 (en) Influenza virus vaccines and uses thereof
Stepanova et al. Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes
WO2018028635A1 (zh) 一种寨卡病毒人源单克隆抗体及其应用
JP2019506841A5 (https=)
JP2013502226A5 (https=)
IL278014B1 (en) Anti-myostatin antibodies, polypeptides containing variable fc regions and methods of use
JP2016505635A5 (https=)
JP2008056679A5 (https=)
JP2012115277A5 (https=)
JP2017514522A5 (https=)
JP2012511545A5 (https=)
JP2014510519A5 (https=)
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
JP2019531293A5 (https=)
JP2015524413A5 (https=)
JP2024522385A (ja) ヒトメタニューモウイルスワクチン
KR20220057578A (ko) 인플루엔자 바이러스 백신 및 이의 용도
JP2016518838A5 (https=)
JP2016520534A5 (https=)